Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Leukemia - 1 Jul 2008

Walz C, Cross N C P, Van Etten R A, Reiter A

Abstract excerpt

Constitutively activated mutants of the non-receptor tyrosine kinases (TK) ABL1 (Abelson murine leukemia viral (v-abl) homolog (1) protein) and JAK2 (JAnus Kinase 2 or Just Another Kinase 2) play a central role in the pathogenesis of clinically and morphologically distinct chronic myeloproliferative disorders but are also found in some cases of de novo acute leukemia and lymphoma. Ligand-independent activation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoantigens
Share to Cell Cycle Proteins
Share to Genes, abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Proto-Oncogene Proteins c-abl

Source

Open in PubMed Open full text

Identifiers

PMID: 18528425
DOI: 10.1038/leu.2008.133
PMCID: PMC3490192

Genes

ABL1
JAK2
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.PMID 18528425Read ↗

BCR/ABL-negative chronic myeloproliferative disorders: JAK2 mutation and beyond.Semantic proximity Read ↗

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.Semantic proximity Read ↗

BCR-ABL-negative chronic myeloid leukemia.Semantic proximity Read ↗

Advances in Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: The Evolving Role of Bcr–Abl Mutations and Mutational AnalysisSemantic proximity Read ↗

Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.Semantic proximity Read ↗

JAK2 inhibition for the treatment of hematologic and solid malignanciesSemantic proximity Read ↗

Jak-2 positive myeloproliferative neoplasms.Semantic proximity Read ↗

Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.Semantic proximity Read ↗

ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.Semantic proximity Read ↗

Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.Semantic proximity Read ↗

The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.Semantic proximity Read ↗

Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.